Best time to take rasagiline

Oral rasagiline (Rasagiline), as monotherapy or adjunctive therapy to levodopa, provides a useful option for symptomatic treatment in adults with Parkinson's disease. In patients with early-stage Parkinson's disease, monotherapy with rasagiline 1 mg/day improved disease symptoms compared with placebo. As an adjunct to levodopa in patients with advanced Parkinson's disease, rasagiline 0.5 or 1 mg/day significantly reduces total daily "off" time. Rasagiline is generally well tolerated when administered as monotherapy or adjunctive therapy.

Rasagiline's AUC increased more than proportionally in the 1-6 mg range, while Cmax was dose-proportional. Rasagiline has a mean steady-state half-life of 3 hours, but due to its irreversible inhibition of MAO-B, there is no correlation between pharmacokinetics and its pharmacological effects. Rasagiline is rapidly absorbed, reaching peak plasma concentration (Cmax) in approximately 1 hour. The absolute bioavailability of rasagiline is approximately 36%. Food does not affect the Tmax of rasagiline, but when the drug is taken with a high-fat meal, Cmax and exposure (AUC) are reduced by approximately 60% and 20%, respectively.

The original drug of rasagiline has been launched in China and has entered the category of Class B medical insurance. The common name is rasagiline mesylate tablets, and the specifications areThe price of each box of 1mg*14 tablets may be around RMB 600. The price of the Turkish version of rasagiline's original drug, 1mg*30 tablets, per box sold overseas may be around RMB 310 (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of 1mg*100 tablets per box produced by Indian pharmaceutical factories may be around RMB 240 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultant.